Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Jan, 2019 | Pages:
75 | Publisher: Grand View Research
Industry: Pharmaceutical | Report Format: Electronic (PDF)
The global fabry disease treatment market size is estimated to reach a value of USD 3.12 billion by 2025, according to a new report by Grand View Research, Inc., exhibiting a CAGR of 9.6% during the forecast period. Rising cohort of Fabry disease, increasing adoption of novel therapies such as chaperone treatment, and potential approval of pipeline drugs including substrate reduction therapies and enzyme replacement therapies are providing a fillip to the market. Fabry disease is a rare inherited lysosomal storage disorder caused by genetic mutation that interferes with function of alpha galactosidase enzyme. Fabry disease generally has a late onset with mild symptoms, due to which several patients are often undiagnosed. Standard of care for management of the disease is enzyme replacement therapy (ERT). Sanofi's Fabrazyme and Shire's Replagal are the only approved ERTs in the EU; however in the U.S., only Fabrazyme has been approved. Focus of current clinical trials is to improve the safety and efficacy profile of ERTs and introduction of novel oral therapies that can eliminate the need for intravenous infusions. Recently, Amicus Therapeutics' Galafold has been approved as the first oral chaperone therapy for the treatment of adults in the U.S., Canada, EU, Japan, Australia, Israel, and South Korea. North America held the largest share in the Fabry disease treatment market in 2017, followed by Europe. The growth of the region can be attributed to higher adoption of novel therapies, favorable reimbursement policies, and better healthcare facilities. However, high cost of therapy with ERTs such as Fabrazyme is an impediment for the market in developing regions. Further key findings from the study suggest : • Although the exact prevalence is unknown, Fabry disease affects approximately one in 40,000 males • The enzyme replacement therapy segment led the market with over 85.0% market share in 2017 due to strong sales of Fabrazyme and Replagal. • North America commanded the leading market share of more than 45.0% in the Fabry disease treatment market, followed by Europe, in 2017 • APAC is likely to witness the fastest growth during the forecast period, followed by Latin America, due to increasing healthcare expenditure and rising patient population • Some of the key players in the market are Sanofi S.A.; Shire Plc.; Amicus Therapeutics Inc.; ISU Abxis Co Ltd.; JCR Pharmaceuticals Co Ltd.; Protalix Biotherapeutics Inc.; Idorsia Pharmaceuticals Ltd.; Avrobio Inc.; Greenovation Biotech GmbH; Moderna Therapeutics Inc.; and Green Cross Pharma Pte Ltd.
Table of Contents
Chapter 1 Methodology and Scope
1.1 Research Methodology
1.1.1 Information procurement
1.2 Information or Data Analysis
1.3 Market Formulation & Validation
1.4 Region-wise Market Calculation
1.4.1 Region-Wise Market: Base Estimates
1.4.2 Global Market: CAGR Calculation
1.5 Region-based Segment Share Calculation
1.6 List of Secondary Sources
1.7 List of Primary Sources
1.7.1 Primary interview breakup
1.7.1.1 Data for primary interviews, by sources
1.7.1.2 Data for primary interviews, by region
Chapter 2 Executive Summary
2.1 Market Snapshot
Chapter 3 Fabry Disease Treatment Market Variables, Trends & Scope
3.1 Market Segmentation & Scope
3.2 Market Driver Analysis
3.3 Market Restraint Analysis
3.4 Key Opportunities Prioritized
3.4.1 Key opportunities prioritized, by treatment
3.4.2 Key opportunities prioritized, by region
3.5 Fabry Disease - SWOT Analysis, by Factor (Political & Legal, Economic and Technological)
3.6 Industry Analysis - Porter's
3.7 Fabry Disease: Market Position Analysis, 2017
Chapter 4 Fabry Disease Treatment Market: Treatment Analysis
4.1 Treatment Business Analysis
4.2 Fabry Disease Treatment Market: Treatment Movement Analysis
4.2.1 Enzyme Replacement Therapy (ERT)
4.2.1.1 Enzyme Replacement Therapy (ERT) market estimates and forecasts, 2016 - 2025 (USD Million)
4.2.2 Chaperone Treatment
4.2.2.1 Chaperone Treatment market estimates and forecasts, 2016 - 2025 (USD Million)
4.2.3 Substrate Reduction Therapy (SRT)
4.2.3.1 Substrate Reduction Therapy (SRT) market estimates and forecasts, 2016 - 2025 (USD Million)
4.2.4 Others
4.2.4.1 Others market estimates and forecasts, 2016 - 2025 (USD Million)
Chapter 5 Fabry Disease Treatment Market: Regional Estimates & Trend Analysis, by Treatment
5.1 Fabry Disease Treatment Market Share by Region, 2017 & 2025
5.2 North America
5.2.1 North America
5.2.1.1 North America Fabry Disease Treatment Market, by treatment, 2016 - 2025 (USD Million)
5.2.2 U.S.
5.2.2.1 U.S. Fabry Disease Treatment Market, by treatment, 2016 - 2025 (USD Million)
5.2.3 Canada
5.2.3.1 Canada Fabry Disease Treatment Market, by treatment, 2016 - 2025 (USD Million)
5.3 Europe
5.3.1 Europe
5.3.1.1 Europe Fabry Disease Treatment Market, by treatment, 2016 - 2025 (USD Million)
5.3.2 Germany
5.3.2.1 Germany Fabry Disease Treatment Market, by treatment, 2016 - 2025 (USD Million)
5.3.3 U.K.
5.3.3.1 U.K. Fabry Disease Treatment Market, by treatment, 2016 - 2025 (USD Million)
5.4 Asia Pacific
5.4.1 Asia Pacific
5.4.1.1 Asia Pacific Fabry Disease Treatment Market, by treatment, 2016 - 2025 (USD Million)
5.4.2 Japan
5.4.2.1 Japan Fabry Disease Treatment Market, by treatment, 2016 - 2025 (USD Million)
5.4.3 China
5.4.3.1 China Fabry Disease Treatment Market, by treatment, 2016 - 2025 (USD Million)
5.4.4 India
5.4.4.1 India Fabry Disease Treatment Market, by treatment, 2016 - 2025 (USD Million)
5.5 Latin America
5.5.1 Latin America
5.5.1.1 Latin America Fabry Disease Treatment Market, by treatment, 2016 - 2025 (USD Million)
5.5.2 Brazil
5.5.2.1 Brazil Fabry Disease Treatment Market, by treatment, 2016 - 2025 (USD Million)
5.5.3 Mexico
5.5.3.1 Mexico Fabry Disease Treatment Market, by treatment, 2016 - 2025 (USD Million)
5.6 MEA
5.6.1 MEA
5.6.1.1 MEA Fabry Disease Treatment Market, by treatment, 2016 - 2025 (USD Million)
5.6.2 South Africa
5.6.2.1 South Africa Fabry Disease Treatment Market, by treatment, 2016 - 2025 (USD Million)
Chapter 6 Competitive Landscape
6.1 Company Profiles
6.1.1 Sanofi S.A.
6.1.1.1 Company Overview
6.1.1.2 Financial Performance
6.1.1.3 Product Benchmarking
6.1.1.4 Strategic Initiatives
6.1.2 Shire Plc.
6.1.2.1 Company Overview
6.1.2.2 Financial Performance
6.1.2.3 Product Benchmarking
6.1.2.4 Strategic Initiatives
6.1.3 Amicus Therapeutics Inc.
6.1.3.1 Company Overview
6.1.3.2 Financial Performance
6.1.3.3 Product Benchmarking
6.1.3.4 Strategic Initiatives
6.1.4 ISU Abxis Co Ltd.
6.1.4.1 Company Overview
6.1.4.2 Financial Performance
6.1.4.3 Product Benchmarking
6.1.4.4 Strategic Initiatives
6.1.5 JCR Pharmaceuticals Co Ltd.
6.1.5.1 Company Overview
6.1.5.2 Financial Performance
6.1.5.3 Strategic Initiatives
6.1.6 Protalix Biotherapeutics Inc.
6.1.6.1 Company Overview
6.1.6.2 Financial Performance
6.1.6.3 Strategic Initiatives
6.1.7 Idorsia Pharmaceuticals Ltd.
6.1.7.1 Company Overview
6.1.7.2 Financial Performance
6.1.7.3 Strategic Initiatives
6.1.8 Avrobio Inc.
6.1.8.1 Company Overview
6.1.8.2 Financial Performance
6.1.8.3 Strategic Initiatives
List of Tables Table 1 Global Fabry Disease Treatment Market, by country, 2016 - 2025 (USD Million) Table 2 Global Fabry Disease Treatment Market, by treatment, 2016 - 2025 (USD Million) Table 3 North America Fabry Disease Treatment Market, by country, 2016 - 2025 (USD Million) Table 4 North America Fabry Disease Treatment Market, by treatment, 2016 - 2025 (USD Million) Table 5 U.S. Fabry Disease Treatment Market, by treatment, 2016 - 2025 (USD Million) Table 6 Canada Fabry Disease Treatment Market, by treatment, 2016 - 2025 (USD Million) Table 7 Europe Fabry Disease Treatment Market, by country, 2016 - 2025 (USD Million) Table 8 Europe Fabry Disease Treatment Market, by treatment, 2016 - 2025 (USD Million) Table 9 U.K. Fabry Disease Treatment Market, by treatment, 2016 - 2025 (USD Million) Table 10 Germany Fabry Disease Treatment Market, by treatment, 2016 - 2025 (USD Million) Table 11 Asia Pacific Fabry Disease Treatment Market, by country, 2016 - 2025 (USD Million) Table 12 Asia Pacific Fabry Disease Treatment Market, by treatment, 2016 - 2025 (USD Million) Table 13 Japan Fabry Disease Treatment Market, by treatment, 2016 - 2025 (USD Million) Table 14 China Fabry Disease Treatment Market, by treatment, 2016 - 2025 (USD Million) Table 15 India Fabry Disease Treatment Market, by treatment, 2016 - 2025 (USD Million) Table 16 Latin America Fabry Disease Treatment Market, by country, 2016 - 2025 (USD Million) Table 17 Latin America Fabry Disease Treatment Market, by treatment, 2016 - 2025 (USD Million) Table 18 Brazil Fabry Disease Treatment Market, by treatment, 2016 - 2025 (USD Million) Table 19 Mexico Fabry Disease Treatment Market, by treatment, 2016 - 2025 (USD Million) Table 20 MEA Fabry Disease Treatment Market, by country, 2016 - 2025 (USD Million) Table 21 MEA Fabry Disease Treatment Market, by treatment, 2016 - 2025 (USD Million) Table 22 South Africa Fabry Disease Treatment Market, by treatment, 2016 - 2025 (USD Million)
List of Figures Fig.1 Market research process Fig.2 Information procurement Fig.3 Primary research pattern Fig.4 Market research approaches Fig.5 Value-chain-based sizing & forecasting Fig.6 QFD modeling for market share assessment Fig.7 Market formulation & validation Fig.8 Primary interviews, by sources Fig.9 Primary interviews, by region Fig.10 Fabry Disease Treatment Market summary Fig.11 Fabry Disease Treatment Market trends and outlook Fig.12 Fabry Disease Treatment Market segmentation Fig.13 Fabry Disease Treatment Market driver impact Fig.14 Fabry Disease Treatment Market restraint impact Fig.15 Key opportunities prioritized, Treatment Fig.16 Key opportunities prioritized, Region Fig.17 SWOT analysis, by factor (political & legal, economic and technological) Fig.18 Porter's five forces analysis Fig.19 Fabry disease outlook: Key takeaways Fig.20 Fabry Disease Treatment Market: Treatment analysis Fig.21 Enzyme Replacement Therapy (ERT) market, 2016 - 2025 (USD Million) Fig.22 Chaperone Treatment market, 2016 - 2025 (USD Million) Fig.23 Substrate Reduction Therapy (SRT) market, 2016 - 2025 (USD Million) Fig.24 Others market, 2016 - 2025 (USD Million) Fig.25 Regional market place: Key takeaways Fig.26 Regional outlook, 2017 & 2025
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
